| Company Name: |
Nanjing Shizhou Biology Technology Co.,Ltd
|
| Tel: |
025-85563444 18351873721 |
| Email: |
purchase@synzest.com |
| Products Intro: |
Product Name:2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethy l)-5-(2-hydroxypropan-2-yl)-1-methyl-1,2,3,4-tetrah ydroisoquinolin-2-yl]ethan-1-one
CAS:1638667-81-8
Purity:95%HPLC Package:1g;5g
|
|
| | 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethy l)-5-(2-hydroxypropan-2-yl)-1-methyl-1,2,3,4-tetrah ydroisoquinolin-2-yl]ethan-1-one Basic information |
| Product Name: | 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethy l)-5-(2-hydroxypropan-2-yl)-1-methyl-1,2,3,4-tetrah ydroisoquinolin-2-yl]ethan-1-one | | Synonyms: | 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethy l)-5-(2-hydroxypropan-2-yl)-1-methyl-1,2,3,4-tetrah ydroisoquinolin-2-yl]ethan-1-one;Ethanone, 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3,4-dihydro-3-(hydroxymethyl)-5-(1-hydroxy-1-methylethyl)-1-methyl-2(1H)-isoquinolinyl]- | | CAS: | 1638667-81-8 | | MF: | C22H25Cl2NO3 | | MW: | 422.34 | | EINECS: | | | Product Categories: | | | Mol File: | 1638667-81-8.mol | ![2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethy l)-5-(2-hydroxypropan-2-yl)-1-methyl-1,2,3,4-tetrah ydroisoquinolin-2-yl]ethan-1-one Structure](CAS/20200611/GIF/1638667-81-8.gif) |
| | 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethy l)-5-(2-hydroxypropan-2-yl)-1-methyl-1,2,3,4-tetrah ydroisoquinolin-2-yl]ethan-1-one Chemical Properties |
| Boiling point | 590.8±50.0 °C(Predicted) | | density | 1.282±0.06 g/cm3(Predicted) | | pka | 14.43±0.29(Predicted) |
| | 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethy l)-5-(2-hydroxypropan-2-yl)-1-methyl-1,2,3,4-tetrah ydroisoquinolin-2-yl]ethan-1-one Usage And Synthesis |
| Uses | DETQ is a selective, allosteric and orally active dopamine D1 receptor (Dopamine Receptor) potentiator. In HEK293 cells expressing the human D1 receptor, DETQ increases cAMP with an EC50 of 5.8 nM and a Kb of 26 nM. DETQ shows ~30-fold less potent at rat and mouse D1 receptors and is inactive at the human D5 receptor[1]. | | in vivo | DETQ (10 mg/kg; i.p.; once) ameliorates subchronic Phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice[2]. | Animal Model: | Mice genetically modified to express the human D1 receptor ("hD1 mice")[2] | | Dosage: | 10 mg/kg | | Administration: | i.p.; once | | Result: | Ameliorated subchronic Phencyclidine-induced object recognition memory deficits.
|
| | IC 50 | Human D1 Receptor: 5.8 nM (EC50) | | References | [1] Kjell A Svensson, et al. An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis. J Pharmacol Exp Ther. 2017 Jan;360(1):117-128. DOI:10.1124/jpet.116.236372
[2] Herbert Y Meltzer, et al. The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice. Behav Brain Res. 2019 Apr 1;361:139-150. DOI:10.1016/j.bbr.2018.12.006 |
| | 2-(2,6-dichlorophenyl)-1-[(1S,3R)-3-(hydroxymethy l)-5-(2-hydroxypropan-2-yl)-1-methyl-1,2,3,4-tetrah ydroisoquinolin-2-yl]ethan-1-one Preparation Products And Raw materials |
|